

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 30 JUNE 2021

(The figures have not been audited)

	INDIVIDUAL QUARTER		CUMULATIVE QUARTER	
	Current Year Quarter ended 30 Jun 2021 (Unaudited) RM'000	Preceding Year Corresponding Quarter 30 Jun 2020 (Unaudited) RM'000	Current Year To-Date 30 Jun 2021 (Unaudited) RM'000	Preceding Year Corresponding Period 30 Jun 2020 (Unaudited) RM'000
Revenue	8,656	3,470	14,134	6,921
Cost of sale	(6,342)	(2,239)	(10,494)	(4,618)
Gross profit	2,314	1,231	3,640	2,303
Other Operating Income	277	508	533	626
Administrative and distribution expenses	(1,171)	(1,016)	(2,462)	(2,187)
Other Operating Expenses	(137)	(587)	(1,884)	(943)
Share of net (loss)/ profit from an associate	(81)	(21)	(153)	(53)
Profit/(loss) before tax	1,202	115	(326)	(254)
Income tax expense	B5 (450)	-	(450)	-
Profit/(loss) after tax	752	115	(776)	(254)
Attributable to :				
Equity holders of the parent	438	64	(1,218)	(332)
Non-controlling Interest	314	51	442	78
	752	115	(776)	(254)
Earnings per share attributable to equity holders of parent :				
Basic (sen)	B13 0.100	0.021	(0.278)	(0.108)
Diluted (sen)	B13 0.099	0.035	(0.275)	(0.182)
EBITDA ⁽¹⁾	1,456	293	216	224

Note:-

⁽¹⁾ Profit before interest income, finance cost, tax, depreciation, amortisation and allowances.

(The unaudited Condensed Consolidated Income Statements should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2021
(The figures have not been audited)

	Unaudited 30 Jun 2021 RM'000	Audited 31 Dec 2020 RM'000
ASSETS		
Non-current assets		
Property, plant and equipment	21,570	11,072
Investment in an associated company	310	463
Intangible assets	44	136
Right-of-use assets	2,493	2,685
Goodwill	8	8
	<u>24,425</u>	<u>14,364</u>
Current Assets		
Inventories	4,699	1,816
Trade receivables	3,564	3,485
Other receivables	6,679	1,325
Contract Assets	11,178	4,262
Amount due from an associate	1,279	7,739
Tax recoverable	-	286
Other short term investments	29,578	31,341
Deposit, cash and bank balances	23,055	18,640
	<u>80,032</u>	<u>68,894</u>
TOTAL ASSETS	<u>104,457</u>	<u>83,258</u>
EQUITY AND LIABILITIES		
Equity attributable to equity holders of the parent		
Share capital	79,769	65,863
Treasury shares	(79)	(79)
Reserves	4,360	5,694
	<u>84,050</u>	<u>71,478</u>
Share Application Money	622	660
Non-controlling interest	1,821	1,379
Total equity	<u>86,493</u>	<u>73,517</u>
Non-Current Liabilities		
Term Loan	B7 5,387	5,915
Lease liabilities	B7 246	292
	<u>5,633</u>	<u>6,207</u>
Current Liabilities		
Trade payables	3,670	1,133
Other payable & accruals	7,423	1,127
Contract Liabilities	348	583
Term Loan	B7 655	439
Lease liabilities	B7 146	252
Taxation	89	-
	<u>12,331</u>	<u>3,534</u>
Total liabilities	<u>17,964</u>	<u>9,741</u>
TOTAL EQUITY AND LIABILITIES	<u>104,457</u>	<u>83,258</u>
Number of ordinary shares in issue ('000)	437,457	368,506
Net assets value per share (RM)	<u>0.1921</u>	<u>0.1940</u>

(The unaudited Condensed Consolidated Balance Sheet should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements)

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED 30 JUNE 2021
(The figures have not been audited)

	6 months Ended 30 Jun 2021 (Unaudited) RM'000	6 months Ended 30 Jun 2020 (Unaudited) RM'000
CASHFLOWS FROM OPERATING ACTIVITIES		
Loss before taxation	(326)	(254)
Adjustment for :		
Depreciation of property, plant and equipment	355	752
Depreciation of right-of-use assets	172	-
Amortisation of intangible assets	7	7
Unrealised loss/(gain) on foreign exchange	15	-
Gain on disposal of short term investment	(26)	(193)
Dividend income from short term investments	(393)	(33)
Interest income	(35)	(116)
Net (reversal of)/impairment losses on trade receivables	(7)	(89)
Interest expense - others	31	97
Reversal of interest expense on lease	-	(261)
Net loss on changes in fair value of short term investments	1,104	135
Property, plant and equipment written off	131	6
Share of loss/ (profit) in an associate	153	53
Operating profit/(loss) before working capital changes	<u>1,181</u>	<u>104</u>
Working capital changes :		
(Increase)/ Decrease in inventories	(2,883)	(291)
(Increase)/ Decrease in contract assets	(6,915)	(2,199)
(Increase)/ Decrease in trade and other receivables	(5,432)	2,059
(Increase)/ Decrease in amount due from associate	6,459	79
Increase in contract liabilities	(234)	198
(Decrease)/ Increase in trade and other payables	8,832	(469)
Cash generated from/(used in) operating activities	<u>1,008</u>	<u>(519)</u>
Interest paid	(31)	(97)
Tax paid	(76)	(112)
Net cash generated from/(used in) operating activities	<u>901</u>	<u>(728)</u>
CASH FLOWS FROM INVESTING ACTIVITIES		
Net withdrawal/(placements) of short term investments	1,073	(725)
Interest received	35	116
Proceeds from disposal of property, plant and equipment	-	6
Purchase of property, plant and equipment (include PPE WIP)	(10,900)	(49)
Acquisition of additional shares in a subsidiary	-	(450)
Net cash (used in)/generated from investing activities	<u>(9,792)</u>	<u>(1,102)</u>
CASHFLOWS FROM FINANCING ACTIVITIES		
Proceeds from issuance of shares	13,130	-
Payments received for exercise of share options and warrants, pending allotment	622	-
Repayment of term loan	(311)	(153)
Addition/(Repayments) of principal portion of lease liabilities	(151)	201
Net withdrawal/(placement) of deposits under lien	1,154	-
Purchase of treasury share	-	(66)
Net cash generated from/(used in) financing activities	<u>14,444</u>	<u>(18)</u>
Net Increase/(decrease) in cash and cash equivalents	5,553	(1,848)
Cash and cash equivalents at beginning period	10,909	9,133
Cash and cash equivalents at end of period	<u>16,462</u>	<u>7,285</u>

Cash and cash equivalents as at 30 Jun 2021 and 30 Jun 2020 comprise the following :

	2021 RM'000	2020 RM'000
Deposit, cash and bank balances	23,055	14,815
Less: Fixed deposits with licensed banks (pledged with bank for banking facilit	(6,593)	7,530
Cash and cash equivalents	<u>16,462</u>	<u>7,285</u>

(The unaudited Condensed Consolidated Cashflow Statements should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 30 JUNE 2021
(The figures have not been audited)

	Attributable to Equity Holders of the SGB							
	<-----Non-distributable----->			Distributable				
	Share Capital RM'000	Option Reserve RM'000	Treasury Shares RM'000	Retained Earnings RM'000	Total RM'000	Share Application Money RM'000	Non-controlling Interests RM'000	Total RM'000
As at 1 January 2020 (audited)	31,089	212	(13)	6,351	37,639	-	1,197	38,836
Loss for the financial year and total comprehensive loss for the financial year	-	-	-	(332)	(332)	-	78	(254)
ESOS forfeited	-	(25)	-	25	-	-	-	-
Purchase of treasury shares	-	-	(66)	-	(66)	-	-	(66)
Arising from additional investment	0	0	-	-	-	0	50	50
At 30 Jun 2020 (unaudited)	31,089	187	(79)	6,044	37,241	-	1,325	38,566
As at 1 January 2021 (audited)	65,863	243	(79)	5,451	71,478	660	1,379	73,517
Issuance of ordinary shares pursuant to:-								
- Exercise of ESOS	254	-	-	-	254	(38)	-	216
- Exercise of Warrants	13,536	-	-	-	13,536	(622)	-	12,914
Payments received for exercise of share options and warrants, pending allotment	-	-	-	-	-	622	-	622
Transferred to share capital upon exercise of ESOS	116	(116)	-	-	-	-	-	-
Loss for the financial year and total comprehensive loss for the financial year	-	-	-	(1,218)	(1,218)	-	442	(776)
At 30 Jun 2021 (unaudited)	79,769	127	(79)	4,233	84,050	622	1,821	86,493

¹ Effective from 31st January 2017, the new Companies Act 2016 ("the Act") abolished the concept of authorised share capital and par value of share capital. Consequently, the credit balance of the share premium becomes part of the Company's share capital pursuant to the transitional provision set out in Section 618(2) of the Act. Notwithstanding this provision, the Company may within 24 months from the commencement of the Act, use this amount for purpose set out in Section 618 (3) of the Act. There is no impact on the number of ordinary shares in issue or the relative entitlement of any members as a result of this transition.

(The unaudited Condensed Consolidated Changes In Equity should be read in conjunction with the accompanying explanatory notes attached to the interim financial statements.)

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE QUARTER ENDED 30 JUNE 2021

A. EXPLANATORY NOTES PURSUANT TO MFRS 134 INTERIM FINANCIAL REPORTING

A1. Basis of preparation

The interim financial report of the Company and its subsidiaries ("Group") is unaudited and is prepared in accordance with MFRS 134 "Interim Financial Reporting" and Paragraph 9.22 of the Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") for the ACE Market and should be read in conjunction with the audited consolidated financial statements of the Group for the financial year ended 31 December 2020.

A2. Changes in accounting policies

The accounting policies adopted by the Group in the interim financial report are consistent with those adopted for the audited financial statements of the Group for the financial year ended 31 December 2020. During the financial period, the Group has adopted the following standards, amendments and IC Interpretations issued by the Malaysian Accounting Standards Board ("MASB"), which became effective for annual period beginning on or after 1 January 2020.

MFRSs/ Amendments/ Interpretations

Amendments to MFRS 3, Business Combinations (Definition of a Business)
Amendments to MFRS 7, Financial Instruments (Disclosure - Interest Rate Benchmark Reform)
Amendments to MFRS 9, Financial Instruments
Amendments to MFRS 101, Presentation of Financial Statements (Definition of Material)
Amendments to MFRS 108, Accounting Policies, Changes in Accounting Estimates and Errors (Definition of Material)
Amendments to MFRS 139, Financial Instruments (Recognition and Measurement)

MFRSs, interpretations and amendments effective for annual periods beginning on or after 1 Jun 2020
Amendments to MFRS 16, Leases – Covid-19-Related Rent Concessions

The adoption of the above did not have any significant impact on the financial statements of the Group.

The Group have not applied the following standards and amendments that have been issued by the MASB which are not yet effective:

Effective for annual periods beginning on or after 1 January 2021

MFRS 17, Insurance Contracts

Effective for annual periods beginning on or after a date to be determined by MASB

Amendments to MFRS 10 and MFRS 128 - Sale or Contribution of Assets between an Investor and its Associates or Joint Ventures

A3. Auditors' report on preceeding annual financial statements

The auditors' report on the financial statements for the financial year ended 31 December 2020 was not subject to any qualification.

A4. Seasonality or cyclical factors

The Group's operations were not affected by seasonal or cyclical changes.

A5. Unusual items affecting assets, liabilities, equity, net income or cash flows

There were no unusual items or events affecting assets, liabilities, equity, net income or cash flows of the Group during the quarter under review.

A6. Material changes in estimates

There were no material changes in estimates that have a material effect in the current quarter results.

A7. Debts and equity securities

There were no other issuance, cancellation, resale, repurchase and repayment of debt and equity securities.

A8. Dividends Paid

There was no dividend paid during the quarter under review.

A. EXPLANATORY NOTES PURSUANT TO MFRS 134 INTERIM FINANCIAL REPORTING (CONTD.)

A9. Segmental information

During the financial period, the Group revenue was contributed mainly from the following business segments:

- i) Engineering Equipment Design and development of equipment and software for engineering education, research and technical and vocational training ("TVET") in chemical, mechanical, electrical, civil and control engineering under SOLTEQ brand, including metal
- ii) Industrial Fabrication and Assembly Metal fabrication and assembly works.
- iii) Industrial Automation Provision of industrial automation solutions, currently specialising in water works such as remote monitoring system for dams, tidal control system for irrigation and automation system for flood mitigation under SOLWEB brand.
- iv) Solar Business Promoting all types of businesses relating to green and renewal energy.
- v) Biotechnology Undertakes all types and kinds of biotechnology business.
- vi) Industrial Lubricants Production and distribution of industrial lubricants under SOLMAX brand and OEM brand.

Segmental financial information for 6 months period ended 30 Jun 2021 and 30 Jun 2020 are as follows:

	2021								
	Engineering Equipment	Industrial Fabrication and Assembly	Industrial Automation	Industrial Lubricants	Biotechnology	Solar Business	Others	Elimination	Total
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Segment revenue									
External	2,991	823	2,350	537	53	7,336	44	-	14,134
Inter-segment	7	488	107	-	-	-	-	(602)	-
Total revenue	2,998	1,311	2,457	537	53	7,336	44	(602)	14,134

Results									
Segment results	(117)	89	537	(80)	(125)	1,359	(1,805)		(142)
Share of loss in an associate									(153)
Interest expense									(31)
Loss before taxation ("LBT")									(326)
Income tax expense									(450)
Loss after taxation ("LAT")									(776)
Non-controlling Interest									(442)
Profit attributable to equity holders of the company									(1,218)

	2020								
	Engineering Equipment	Industrial Fabrication and Assembly	Industrial Automation	Industrial Lubricants	Biotechnology	Solar Business	Others	Elimination	Total
	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000	RM'000
Segment revenue									
External	3,473	1,669	1,029	582	8	122	38	-	6,921
Inter-segment	2	173	50	9	-	-	-	234	-
Total revenue	3,475	1,842	1,079	591	8	122	38	(234)	6,921

Results									
Segment results	106	132	270	(31)	(51)	(4)	(526)		(104)
Share of loss in an associate									(53)
Interest expense									(97)
Loss before taxation ("LBT")									(254)
Income tax expense									-
Loss after taxation ("LAT")									(254)
Non-controlling Interest									(78)
Profit attributable to equity holders of the company									(332)

A10. Valuation of property, plant and equipment

The Group did not revalue any of its property, plant and equipment during the quarter under review.

A11. Material events subsequent to the end of the quarter

There were no material events occurring subsequent to the end of the reporting period to the date of announcement.

A12. Changes in the composition of the Group

There were no changes in the composition of the Group for the quarter under review.

A13. Contingent liabilities

There were no material contingent liabilities as at the date of this announcement.

A14. Capital commitment

As at the quarter ended, the Group's wholly-owned subsidiary Solution Biologics Sdn. Bhd has committed RM2.7 mil for establishing a Fill & Finish facility for COVID-19 vaccine at Technology Park Malaysia.

A15. Significant Related Party Transaction

Year-to-date
30 Jun 2021
RM'000

Income

Sales to an associate

162

The Group had obtained the shareholders' mandate to enter into recurrent related party transactions of a revenue or trading nature at Seventeenth Annual General Meeting of the Company.

B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD LISTING REQUIREMENTS FOR THE ACE MARKET

B1. Review of Performance

Comparison with corresponding quarter in previous financial year

The Group recorded a revenue of RM8.65 million during the quarter, an increase of RM5.18 million as compared to the revenue of RM3.47 million in the corresponding quarter in previous financial year. The increase in revenue was mainly attributable to Solar Business projects.

For the quarter ended 30 June 2021, the Group recorded a profit after tax ("PAT") of RM0.75 million against PAT of RM0.11 million reported in the preceding year quarter ended 30 June 2020. The higher profit during the quarter was associated with the higher sales during the quarter.

B2. Comparison with Preceding Quarter's Results

The Group's revenue for the quarter under review was RM8.65 million, an increase of RM3.17 million, as compared to the revenue of RM5.48 million registered in the preceding quarter. The significant increase is mainly due to the higher sales being recognised from the Solar Business during the quarter.

The Group reported a profit of RM0.75 million during the quarter, as compared to the loss of RM1.53 million in the preceding quarter. The profit reported in this quarter was mainly attributed to the higher sales achieved in the current quarter.

B3. Prospects for this financial year ending 31 December 2021

The operating environment of the Group business segments of engineering equipment, industrial fabrication and assembly and biotechnology remain challenging during this COVID-19 pandemic. However, the Group has achieved satisfactory results for its other 2 business segments, i.e. solar and bio-pharmaceutical.

The solar business is growing, in order to move up the value chain, the paid up capital of the subsidiary, Solar Solution Sdn Bhd has increased to RM1 million. With the increased in paid-up the company will be able to upgrade its CIDB license and eligible to bid for solar construction projects.

The Group's new business, bio-pharmaceutical, has been progressing favourably. On 1 April 2021, the Group's wholly-owned subsidiary, Solution Biologics Sdn Bhd ("SOLBIO") has successfully signed a Supply Agreement with the Ministry of Health to supply 3.5 millions doses of COVID-19 vaccines.

On 16 June 2021, SOLBIO had received the product registration conditional approval from Drug Control Authority for its CONVIDECLA (Trade Mark) Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) for emergency use. The vaccine is for the prevention of COVID-19.

On 30 July 2021, SOLBIO had entered into 2 Supply Agreements ("the Agreement") with CanSino Biologics Inc ("CanSino") for the supply of COVID-19 vaccine in both finished product and bulk form.

On 20 August 2021, SOLBIO delivered 200,000 doses of CanSino COVID-19 vaccines to MOH. This is the first delivery and SOLBIO is expecting to fulfill the supply of the 3.5 million doses to MOH by the fourth quarter of 2021.

SOLBIO has also finished establishing its Formulation, Fill & Finish facility at Technology Park Malaysia. The Good Manufacturing Practice ("GMP") audit will be conducted by NPRA in September with the certification expected to be issued in October 2021.

The solar and bio-pharmaceutical businesses will contribute positively to the Group revenue for the financial year ending 2021.

With the collaboration with CanSino, the Board is optimistic with the Group's future growth.

B4. Profit guarantee

The Group has not issued any profit forecast nor guarantee in respect of any corporate proposal.

B5. Taxation

	Quarter ended		Year-to-date	
	30 Jun 2021	30 Jun 2020	30 Jun 2021	30 Jun 2020
	RM'000	RM'000	RM'000	RM'000
Current taxation				
-Provision for taxation	(450)	-	(450)	-
Deferred taxation	-	-	-	-
	<u>(450)</u>	<u>-</u>	<u>(450)</u>	<u>-</u>

B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD LISTING REQUIREMENTS FOR THE ACE MARKET (CONTD.)

B6. Profit on sale of unquoted investments and/or properties

There were no disposal of unquoted investment and/or properties for the quarter under review.

B7. Group borrowings and debt securities

Details of the Group's borrowings as at 30 Jun 2021 are as follows :

	Current RM'000	Non-current RM'000	Total RM'000
Secured :			
Hire purchase (included in lease liabilities)	146	246	392
Term loan	655	5,387	6,042
Total	801	5,633	6,434

B8. Status of Corporate Proposals

A) Update on Employees' Share Option Scheme (ESOS) as at 30 June 2021

The Company had obtained its shareholders approval for the establishment of the ESOS of up to 30% of the total issued and paid-up share capital for the eligible employees and directors and its subsidiaries at the EGM dated 16 January 2014.

Below show the details of the shares that had been granted and exercised under the ESOS as at 30 June 2021:

ESOS Option Grant Date	Expiry Date	Exercise Price	No. of Share			Status
			No. of Share Granted	Exercised and Listed	No. of Share Lapsed	
22 July 2014	29 Jan 2019	RM0.135	11,134,000	11,103,000	31,000	Completed
8 January 2015	29 Jan 2019	RM0.185	6,000,000	6,000,000	-	Completed
28 September 2016	29 Jan 2024	RM0.220	6,000,000	4,473,000	422,000	Ongoing
8 August 2020	29 Jan 2024	RM0.175	2,605,000	2,141,000		Ongoing

On 22 January 2019, the Company had announced to extend the existing ESOS of the Company which commenced on 30 January 2014 and expired on 29 January 2019 for another five (5) years until 29 January 2024 in accordance with the terms of the ESOS Bylaws.

B) Proposed Renewal of Authority for the Company to Purchase Its Own Shares

The Renewal of Authority for Share Buy Back had been approved by shareholders at the seventeenth Annual General Meeting of the Company. As at todate, the total number of treasury shares is 1,462,700, there is no any changes during the quarter.

C) Utilisation of proceeds

On 5 November 2020, the Company announced to undertake a private placement of up to 30,857,600 new ordinary shares in SGB, representing not more than 10% of the total number of issued shares in SGB ("The Proposed Private Placement"). The Private Placement has been completed successfully on 9 December 2020 and had raised a total proceeds of RM28.265 million. The proceeds has been utilised by the Group to set up a facility to carry out the formulation, fill and finish process of the CanSino COVID-19 vaccine, the breakdown of the utilisation are as follows:

Purpose	Timeframe for Utilisation of Proceeds	Proposed Utilisation RM'000	Actual Utilisation RM'000
Set up of fill and finish facility	Within 6 months	10,219	10,219
Purchase of production machineries and equipment	Within 6 months	5,000	5,000
Purchase of quality assurance and control equipment	Within 6 months	3,000	3,000
Expenses for The Proposed Private Placement	Within 1 month	450	450
Total		18,669	18,669

The excess proceeds of RM9.596 million has been utilised for the working capital.

B9. Realised/ Unrealised Profits

	As at 30 Jun 2021 RM'000
Total retained earnings of the Company and its subsidiaries	
- realised	14,056
- unrealised	(1,105)
	<u>12,951</u>
Total share of accumulated loss of an associate	
- realised	(450)
	<u>12,501</u>
Less: Consolidated adjustments	(8,268)
Retained profit as per financial statement	<u>4,233</u>

**B. ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD
LISTING REQUIREMENTS FOR THE ACE MARKET (CONTD.)**

B10. Profit Before Tax

	Quarter ended 30 Jun 2021 RM'000	Quarter ended 30 Jun 2020 RM'000
Profit before tax is derived after charging:		
Depreciation of PPE & ROU	221	490
Amortisation of intangible asset	2	-
Interest expense	17	97
Loss on foreign exchange:		
-Realised	5	79
Loss on disposal of Property, plant and equipments (PPE)	-	13
PPE written off	<u>131</u>	<u>-</u>
and crediting:		
Interest income	-	(59)
Dividend income from other investment	(209)	(27)
Gain on disposal of short term investment	(44)	(9)
Reversal of interest expense (lease)	-	(261)
Reversal of impairment on trade receivables and contract asset	(5)	(89)
Gain on foreign exchange:		
-Realised	<u>(20)</u>	<u>(63)</u>

B11. Off balance sheet financial instruments

There were no financial instruments with off-balance sheet risk as at the date of this announcement applicable to the Group.

B12. Dividends

The Board of Directors did not recommend any payment of dividend in respect of the quarter under review.

B13. Earnings per share

	Current Quarter ended 30 Jun 2021	Comparative Quarter ended 30 Jun 2020	Current year to date ended 30 Jun 2021	Preceding year to date ended 30 Jun 2020
Net profit/(loss) for the period attributable to equity holders (RM'000)	438	64	(1,218)	(332)
Basic				
Weighted average number of ordinary shares in issue ('000)	437,457	306,455	437,457	306,455
Basic EPS (sen)	<u>0.100</u>	<u>0.021</u>	<u>(0.278)</u>	<u>(0.108)</u>
Diluted				
Weighted average number of ordinary shares in issue ('000)	437,457	306,455	437,457	306,455
Effect of dilution: share options and convertible warrants ('000)	5,830	(123,983)	5,830	(123,983)
Adjusted weighted average number of ordinary shares in issue and issuable ('000)	<u>443,287</u>	<u>182,472</u>	<u>443,287</u>	<u>182,472</u>
Diluted EPS (sen)	<u>0.099</u>	<u>0.035</u>	<u>(0.275)</u>	<u>(0.182)</u>

**BY ORDER OF THE BOARD
SOLUTION GROUP BERHAD**